Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan NV    MYL   NL0011031208

MYLAN NV (MYL)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Discover our TOP LISTS, the world's most profitable stocks to hold Get it NOW!
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
37.23(c) 37.42(c) 38.27(c) 39.01(c) 39.03 Last
4 024 543 3 739 015 4 222 955 6 319 879 15 821 635 Volume
+1.39% +0.51% +2.27% +1.93% +0.05% Change
More quotes
Financials ($)
Sales 2017 12 528 M
EBIT 2017 3 733 M
Net income 2017 1 739 M
Debt 2017 12 866 M
Yield 2017 -
Sales 2018 13 094 M
EBIT 2018 4 044 M
Net income 2018 2 344 M
Debt 2018 10 939 M
Yield 2018 -
P/E ratio 2017 13,14
P/E ratio 2018 10,77
EV / Sales2017 2,70x
EV / Sales2018 2,43x
Capitalization 20 909 M
More Financials
Company
Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products.It operates through two segments: Generic and Specialty.The Generic pharmaceutical business is conducted... 
Sector
Pharmaceuticals
Calendar
06/22 | 02:00pmShareholder meeting
More about the company
Surperformance© ratings of Mylan NV
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN NV
06/22 MYLAN : shareholders vote against executive pay, re-elect board
06/10 MYLAN : and Biocon Present Clinical Data on Insulin Glargine at the American Dia..
06/07 MYLAN : to Present at Goldman Sachs 38th Annual Global Healthcare Conference
06/07 Mylan defends chairman to ISS ahead of June 22 investor vote
06/06 JOHN HENDRICKSON : Drugmaker Perrigo says CEO Hendrickson plans to retire
06/05 MYLAN NV : Featured Company News - Mylan Launches Two New Generic Drugs: Generic..
06/02 MYLAN : Launches Generic Azilect® Tablets
06/02 MYLAN : Launches Generic Reclast® Injection
05/23 MYLAN : Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefe..
05/19 Hikma trims full year revenue forecast on Advair U.S. launch delay
More news
Sector news : Pharmaceuticals - NEC
04:34pDJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
01:48pDJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
01:15pDJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
12:20p China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
More sector news : Pharmaceuticals - NEC
Latest Tweets
06:52pRenaissance Technologies LLC Acquires 984,400 Shares of Mylan N.V. $MYL  
06:05pMylan shareholders think this man makes too much money (so does @NoceraBV)  
09:04aMylan elects full board despite oppostion  
03:35aThe Mylan vote signals deep dissension over the $9M in compensation awarded t..
12
12:41aShareholders fail to oust Mylan board, but down-voted massive salaries
5
More tweets
Qtime:97
News from SeekingAlpha
06/22 Mylan shareholders back board but thumbs down on executive pay
06/21 Biotechs blaze as Trump draft order on drug prices would ease regulations
06/19 Mylan Has Once Again Simply Become A Bargain
06/16 Biotech Forum Daily Digest - Spotlight On Fibrocell Science
06/16 Premarket analyst action - healthcare
Advertisement
Chart MYLAN NV
Duration : Period :
Mylan NV Technical Analysis Chart | MYL | NL0011031208 | 4-Traders
Full-screen chart
Technical analysis trends MYLAN NV
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 48,7 $
Spread / Average Target 25%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN NV2.25%20 909
JOHNSON & JOHNSON17.10%366 496
NOVARTIS7.69%225 516
ROCHE HOLDING LTD.8.81%225 056
PFIZER4.86%202 832
MERCK AND COMPANY12.15%180 576
More Results